Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.80 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028039 | 1.00 | ALOX15 (0.80) | ALOX15PTGER4GAABRD4LMNA | |
| SCHEMBL15319752 | 0.95 | ALOX15 (0.88) | ALOX15PTGER4GAABRD4LMNA | |
| SCHEMBL21311003 | 0.90 | ALOX15 (0.65) | ALOX15PTGER4BRD4LMNACYP1A2 | |
| SCHEMBL28849352 | 0.90 | ALOX15 (0.65) | ALOX15PTGER4BRD4LMNACYP1A2 | |
| SCHEMBL15320258 | 0.90 | ALOX15 (0.80) | ALOX15PTGER4GAABRD4LMNA | |
| SCHEMBL15320656 | 0.90 | ALOX15 (0.80) | ALOX15PTGER4GAABRD4LMNA | |
| SCHEMBL15320802 | 0.90 | ALOX15 (0.97) | ALOX15PTGER4GAABRD4LMNA | |
| SCHEMBL15320854 | 0.90 | ALOX15 (0.93) | ALOX15PTGER4GAABRD4LMNA | |
| SCHEMBL15319744 | 0.89 | ALOX15 (1.00) | ALOX15PTGER4GAABRD4LMNA | |
| SCHEMBL2032512 | 0.89 | ALOX15 (1.00) | ALOX15PTGER4GAABRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107021958-A | FXR receptor stimulating agents | 山东轩竹医药科技有限公司 | 2017-08-08 | — | — | CN | disclosed |
| US-8293923-B2 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2011-06-23 | — | — | US | disclosed |
| CN-101616910-A | Indazole derivatives as interleukin 1 receptor associated kinase conditioning agent | BIOGEN IDEC INC | 2009-12-30 | — | — | CN | disclosed |
| EP-2061786-A2 | INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | Biogen Idec MA Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2008030584-A2 | INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN- 1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | ALOX15 2516/4885PTGER4 4135/4885GAA 1157/4885 |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | IRAK1, IRAK2, IRAK3 | ALOX15 2687/4885PTGER4 2250/4885GAA 2223/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | ALOX15 2516/4885PTGER4 4135/4885GAA 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.